OR WAIT null SECS
Stada licenses 3M's transdermal technology for a fentanyl patch.
3M Drug Delivery Systems reports that Stada Arzneimittel AG is licensing 3M’s patented technology directed to a matrix patch for the transdermal delivery of the opioid pain medication fentanyl. Terms of the license agreement were not disclosed.
The 3M Patent, which was granted on March 20, 2013, enables a transdermal drug delivery device designed to deliver a therapeutically effective amount of fentanyl across the skin of a patient. The matrix device is configured by incorporating fentanyl into an adhesive matrix made of a copolymer containing alkyl acrylate and other monomers.
Source: 3M Drug Delivery Systems